~~<i id='99343709EA'><strike id='99343709EA'><tt id='99343709EA'><pre id='99343709EA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

knowledge

author：hotspot 2025-09-30 23:40:33 - browse：87893

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Anthos stroke drug appears safer than common blood thinner

Wikipedia

hotspot

leisure time

focus

Wikipedia

KristofferTripplaar/SipaviaAPTohearSareptaCEODougIngramtellit,theresultsMondayafternoonfromalargetri

WSS

Childhood cancer progress stalls for Black, Hispanic kids: Report

Lung cancer screening guidelines updated for cigarette smokers

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Ransomware attacks on hospitals: Study outlines patient impact

PBM reforms clear House panel

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Wikipedia

knowledge

Wikipedia

In Memoriam: Notable people who died in 2023

Humans aren't the only ones with an imagination. Rats have it too

Guidelines to prevent youth baseball injuries need more muscle

Inari Medical to buy amputation prevention company LimFlow

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

23andMe had bad news about my health. I wish a person had delivered it

After Sarepta trial failure, Duchenne families brace for more debate

Heart attack and stroke risk calculators need revising

CRISPR pioneers react to Casgevy, first gene

hotspot

World's first CRISPR

All of Us, NIH's precision medicine initiative, gets a big boost

Travis Kelce and the trap of celebrity vaccine endorsements

Astellas still sees hope in its gene therapy after four deaths

Coloradans with cystic fibrosis could lose access to Trikafta

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

hotspot

leisure time

focus

Wikipedia